Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Spartex who wrote (859)	8/1/2003 9:24:15 AM
From: rkrw	Read Replies (1) \| Respond to of 3557

Key paragraph from the release: The Company has a Phase I trial underway with the VEGF Trap for cancer. A dose-escalation study, in which subjects receive a weekly, self-administered subcutaneous injection of the VEGF Trap, is currently in progress and an intravenous phase of this study is planned for later this year. This trial is designed to assess the safety and tolerability of this therapeutic candidate in people with solid tumor malignancies or with non-Hodgkin's lymphoma. A pre-clinical study published recently in The Proceedings of the National Academy of Sciences (PNAS) reported that Regeneron's VEGF Trap caused shrinkage of established, growing tumors and their metastases in a mouse model of anaplastic Wilm's Tumor, a highly aggressive kidney tumor. *Regeneron is considering a number of strategies, including possible collaborative arrangements, to accelerate development of the VEGF Trap.*